Security key
918385204
vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT)
CUSIP: 918385204
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Class A Common Stock, par value $0.01 per share
- Total 13F shares
- 378
- Total 13F value
- $14,232
- Share change
- 0
- SEC-reported price per share
- $37.65
- Number of holders
- 3
- Shares outstanding
- 3,948,649
Holder snapshot
3 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
3
VTVT full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
vTv Therapeutics Inc. SEC filings
vTv Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 918385204
Recent filing periods:
Ownership snapshot
Top reported holders of VTVT - vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Samsara BioCapital, L.P.
Disclosed value leader
Samsara BioCapital, L.P.
Comparable rows
15/15
Latest evidence
13 Apr 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.9%
13D/G row: Samsara BioCapital, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Samsara BioCapital, L.P. leads the comparable SEC ownership view at 9.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Samsara BioCapital, L.P.'s linked filing trail.
Comparable ownership
Top 5
Samsara BioCapital, L.P.
9.9%
Trails Edge Capital Partners, LP
9.9%
Invus Global Management, LLC
9.4%
MILLENNIUM MANAGEMENT LLC
5.7%
Samsara BioCapital, LLC
7.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Samsara BioCapital, L.P. |
13D/G
Srinivas Akkaraju
|
9.9%
|
$12,001,117
403,942 shares
|
+$1,803,961 | 08 Dec 2025 |
| Trails Edge Capital Partners, LP |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$5,535,663
139,578 shares
|
— | 31 Mar 2026 |
| Invus Global Management, LLC |
13D/G
Raymond Debbane
|
9.4%
|
$9,179,310
393,098 shares
|
+$1,051,154 | 30 Sep 2025 |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
Company
|
5.7%
|
$8,927,903
225,073 shares
|
+$1,064,496 | 13 Apr 2026 |
| Samsara BioCapital, LLC |
13F
Company
|
7.6%
|
$11,838,351
298,496 shares
|
— | 31 Mar 2026 |
| FMR LLC |
13F
Company
|
6.6%
|
$10,327,107
260,391 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
378
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
35
Q2 2026 holders
3
Holder diff
-32
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend